Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Duewell

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
International Journal of Cancer|May 18, 2010
An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinomaCollin Jacobs, Peter Duewell, Klaus Heckelsmiller, et al.
JCI Insight|March 9, 2018
Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gutRachel Mak'Anyengo, Peter Duewell, Cornelia Reichl, et al.
Cancer Research|January 23, 2013
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancerJonathan Ellermeier, Jiwu Wei, Peter Duewell, et al.
British Journal of Cancer|November 16, 2018
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapyFelicitas Rataj, Severin J Jacobi, Stefan Stoiber, et al.
Journal for Immunotherapy of Cancer|November 8, 2019
Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancerPhilipp Metzger, Sabrina V Kirchleitner, Michael Kluge, et al.
Cancer Immunology, Immunotherapy : CII|May 26, 2020
Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer modelPhilipp Metzger, Sabrina V Kirchleitner, Daniel F R Boehmer, et al.
Journal for Immunotherapy of Cancer|December 18, 2019
Correction to: Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancerPhilipp Metzger, Sabrina V Kirchleitner, Michael Kluge, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 27, 2011
ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cellsPeter Duewell, Ulrich Kisser, Klaus Heckelsmiller, et al.
Journal for Immunotherapy of Cancer|January 22, 2026
RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinomaAnne Marie Senz, Bruno L Cadilha, Julia Teppert, et al.
Cancer Immunology Research|February 9, 2023
IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer ModelVeronika Lutz, Veronique M Hellmund, Felix S R Picard, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
International Journal of Cancer|May 18, 2010
An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinomaCollin Jacobs, Peter Duewell, Klaus Heckelsmiller, et al.
JCI Insight|March 9, 2018
Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gutRachel Mak'Anyengo, Peter Duewell, Cornelia Reichl, et al.
Cancer Research|January 23, 2013
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancerJonathan Ellermeier, Jiwu Wei, Peter Duewell, et al.
British Journal of Cancer|November 16, 2018
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapyFelicitas Rataj, Severin J Jacobi, Stefan Stoiber, et al.
Journal for Immunotherapy of Cancer|November 8, 2019
Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancerPhilipp Metzger, Sabrina V Kirchleitner, Michael Kluge, et al.
Cancer Immunology, Immunotherapy : CII|May 26, 2020
Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer modelPhilipp Metzger, Sabrina V Kirchleitner, Daniel F R Boehmer, et al.
Journal for Immunotherapy of Cancer|December 18, 2019
Correction to: Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancerPhilipp Metzger, Sabrina V Kirchleitner, Michael Kluge, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 27, 2011
ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cellsPeter Duewell, Ulrich Kisser, Klaus Heckelsmiller, et al.
Journal for Immunotherapy of Cancer|January 22, 2026
RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinomaAnne Marie Senz, Bruno L Cadilha, Julia Teppert, et al.
Cancer Immunology Research|February 9, 2023
IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer ModelVeronika Lutz, Veronique M Hellmund, Felix S R Picard, et al.
Pageof 4